JOP20210319A1 - مركبات بيروليدين - Google Patents
مركبات بيروليدينInfo
- Publication number
- JOP20210319A1 JOP20210319A1 JOP/2021/0319A JOP20210319A JOP20210319A1 JO P20210319 A1 JOP20210319 A1 JO P20210319A1 JO P20210319 A JOP20210319 A JO P20210319A JO P20210319 A1 JOP20210319 A1 JO P20210319A1
- Authority
- JO
- Jordan
- Prior art keywords
- formula
- compounds
- pyrrolidine compounds
- nhso2nh
- ch2nhch2
- Prior art date
Links
- 150000003235 pyrrolidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
يوفر الاختراع الحالي مركبات لها صيغة (I) حيث يتم اختيار L من المجموعة المكوّنة من -CH2NHCH2-، -CH2NH-، -NH-، -S-، -S(O)-، -S(O)2-، -O-، -OCH2-، -OCH2CH2O-، -NHSO2NH-، (II) و(III)، أو ملح مقبول صيدليًا مما سبق؛ ومركب له الصيغة: (IV)، وعمليات لتحضير المركبات وأملاحها، وتركيبة صيدلية، وطرق لعلاج مريض بحاجة لتلك المعالجة.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19382477 | 2019-06-07 | ||
PCT/US2020/035825 WO2020247429A1 (en) | 2019-06-07 | 2020-06-03 | Pyrrolidine compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20210319A1 true JOP20210319A1 (ar) | 2023-01-30 |
Family
ID=66821161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2021/0319A JOP20210319A1 (ar) | 2019-06-07 | 2020-06-03 | مركبات بيروليدين |
Country Status (22)
Country | Link |
---|---|
US (2) | US11286249B2 (ar) |
EP (1) | EP3980409A1 (ar) |
JP (2) | JP6940717B2 (ar) |
KR (3) | KR102477481B1 (ar) |
CN (1) | CN114008021A (ar) |
AU (1) | AU2020287599B2 (ar) |
BR (1) | BR112021023347A2 (ar) |
CA (1) | CA3140869A1 (ar) |
CL (1) | CL2021003202A1 (ar) |
CO (1) | CO2021016295A2 (ar) |
CR (1) | CR20210602A (ar) |
DO (1) | DOP2021000254A (ar) |
EA (1) | EA202193007A1 (ar) |
EC (1) | ECSP21088515A (ar) |
IL (1) | IL288174A (ar) |
JO (1) | JOP20210319A1 (ar) |
MA (1) | MA56115A (ar) |
MX (1) | MX2021014913A (ar) |
PE (1) | PE20220134A1 (ar) |
SG (1) | SG11202113244UA (ar) |
WO (1) | WO2020247429A1 (ar) |
ZA (1) | ZA202109251B (ar) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023078333A1 (zh) | 2021-11-03 | 2023-05-11 | 上海拓界生物医药科技有限公司 | 一种取代的苯丙酸衍生物及其用途一种取代的苯丙酸衍生物及其用途 |
WO2023146785A1 (en) | 2022-01-26 | 2023-08-03 | Eli Lilly And Company | Pyrrolidine compounds |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2003016265A1 (ja) * | 2001-08-17 | 2004-12-02 | エーザイ株式会社 | 環状化合物およびpparアゴニスト |
BR0318685A (pt) * | 2003-12-24 | 2006-12-19 | Esperion Therapeutics Inc | compostos de cetona e composições para controle de colesterol e usos relacionados |
AU2003300438A1 (en) * | 2003-12-24 | 2005-08-03 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
-
2020
- 2020-06-03 EP EP20747210.1A patent/EP3980409A1/en active Pending
- 2020-06-03 JP JP2021505713A patent/JP6940717B2/ja active Active
- 2020-06-03 KR KR1020217040065A patent/KR102477481B1/ko active IP Right Grant
- 2020-06-03 WO PCT/US2020/035825 patent/WO2020247429A1/en active Application Filing
- 2020-06-03 PE PE2021002037A patent/PE20220134A1/es unknown
- 2020-06-03 JO JOP/2021/0319A patent/JOP20210319A1/ar unknown
- 2020-06-03 CN CN202080041924.XA patent/CN114008021A/zh active Pending
- 2020-06-03 KR KR1020247002433A patent/KR20240014618A/ko active Application Filing
- 2020-06-03 BR BR112021023347A patent/BR112021023347A2/pt unknown
- 2020-06-03 MA MA056115A patent/MA56115A/fr unknown
- 2020-06-03 CR CR20210602A patent/CR20210602A/es unknown
- 2020-06-03 KR KR1020227043106A patent/KR102629923B1/ko active IP Right Grant
- 2020-06-03 US US17/056,144 patent/US11286249B2/en active Active
- 2020-06-03 SG SG11202113244UA patent/SG11202113244UA/en unknown
- 2020-06-03 MX MX2021014913A patent/MX2021014913A/es unknown
- 2020-06-03 AU AU2020287599A patent/AU2020287599B2/en active Active
- 2020-06-03 CA CA3140869A patent/CA3140869A1/en active Pending
- 2020-06-03 EA EA202193007A patent/EA202193007A1/ru unknown
-
2021
- 2021-09-02 JP JP2021143227A patent/JP2021191784A/ja active Pending
- 2021-11-16 IL IL288174A patent/IL288174A/en unknown
- 2021-11-18 ZA ZA2021/09251A patent/ZA202109251B/en unknown
- 2021-11-30 CO CONC2021/0016295A patent/CO2021016295A2/es unknown
- 2021-12-01 CL CL2021003202A patent/CL2021003202A1/es unknown
- 2021-12-07 DO DO2021000254A patent/DOP2021000254A/es unknown
- 2021-12-07 EC ECSENADI202188515A patent/ECSP21088515A/es unknown
-
2022
- 2022-02-15 US US17/671,806 patent/US20220169636A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020287599B2 (en) | 2023-10-19 |
IL288174A (en) | 2022-01-01 |
BR112021023347A2 (pt) | 2022-04-12 |
CN114008021A (zh) | 2022-02-01 |
ZA202109251B (en) | 2024-04-24 |
KR102477481B1 (ko) | 2022-12-15 |
ECSP21088515A (es) | 2022-01-31 |
JP2021191784A (ja) | 2021-12-16 |
KR20220018494A (ko) | 2022-02-15 |
CR20210602A (es) | 2022-01-06 |
US20220169636A1 (en) | 2022-06-02 |
KR20240014618A (ko) | 2024-02-01 |
JP2021524498A (ja) | 2021-09-13 |
MX2021014913A (es) | 2022-01-18 |
DOP2021000254A (es) | 2022-01-16 |
AU2020287599A1 (en) | 2022-01-06 |
US20210253559A1 (en) | 2021-08-19 |
WO2020247429A1 (en) | 2020-12-10 |
CA3140869A1 (en) | 2020-12-10 |
US11286249B2 (en) | 2022-03-29 |
KR102629923B1 (ko) | 2024-01-30 |
KR20230004890A (ko) | 2023-01-06 |
PE20220134A1 (es) | 2022-01-27 |
EA202193007A1 (ru) | 2022-03-25 |
EP3980409A1 (en) | 2022-04-13 |
SG11202113244UA (en) | 2021-12-30 |
JP6940717B2 (ja) | 2021-09-29 |
CL2021003202A1 (es) | 2022-09-09 |
CO2021016295A2 (es) | 2021-12-10 |
MA56115A (fr) | 2022-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20220230A (es) | Inhibidores de pequeñas moléculas de mutante g12c de kras | |
WO2021147236A9 (zh) | 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用 | |
MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
MX2019012756A (es) | Compuestos de heteroarilo biciclicos 6-6 fusionados y su uso como inhibidores de lats. | |
MX2023007192A (es) | Inhibidores de prmt5. | |
MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
MX2021005050A (es) | Derivados de quinolina como inhibidores de integrina alfa4beta7. | |
MX2012003007A (es) | Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer. | |
MX2022001784A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos. | |
PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
MX2021012105A (es) | Compuestos de pirrol. | |
MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
JOP20210319A1 (ar) | مركبات بيروليدين | |
MX2022006333A (es) | Compuesto triheterociclico como inhibidor de jak y uso del mismo. | |
MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
NZ757711A (en) | Antimicrobial compounds, compositions, and uses thereof | |
MX2023001071A (es) | Tratamiento de la migraña. | |
PH12021551057A1 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
MX2020009287A (es) | Nuevo compuesto y composicion farmaceutica que lo comprende. | |
MX2023003576A (es) | Compuesto como inhibidor de la akt cinasa. | |
MX2019003585A (es) | Derivados de tetrahidropiridina y su uso como agentes antibacterianos. |